144 related articles for article (PubMed ID: 28771807)
1. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
Wang J; Luo L; Wang D; Guo B; Li J; Yang Z; Tang D
J Cell Biochem; 2018 Feb; 119(2):1521-1537. PubMed ID: 28771807
[TBL] [Abstract][Full Text] [Related]
2. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
Ge L; Wang YF; Tian JH; Mao L; Zhang J; Zhang JH; Shen XP; Yang KH
J Clin Pharm Ther; 2016 Aug; 41(4):383-91. PubMed ID: 27338003
[TBL] [Abstract][Full Text] [Related]
3. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
5. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
[TBL] [Abstract][Full Text] [Related]
6. Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China.
Zhang D; Wu J; Duan X; Wang K; Ni M; Liu S; Zhang X; Zhang B; Zhao Y
Integr Cancer Ther; 2019; 18():1534735419827098. PubMed ID: 30791732
[TBL] [Abstract][Full Text] [Related]
7. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
8. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy for colorectal cancers].
Lièvre A; Mitry E
J Chir (Paris); 2003 Feb; 140(1):52-5. PubMed ID: 12709655
[TBL] [Abstract][Full Text] [Related]
10. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Zhao Z; Pelletier E; Barber B; Bhosle M; Wang S; Gao S; Klingman D
Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
[TBL] [Abstract][Full Text] [Related]
11. Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Kajitani T; Makiyama A; Arita S; Shimokawa H; Oda H; Shirakawa T; Baba E; Esaki T
Anticancer Res; 2017 Nov; 37(11):6459-6468. PubMed ID: 29061833
[TBL] [Abstract][Full Text] [Related]
12. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Mishima H; Ikenaga M; Yasui M
Nihon Rinsho; 2011 Apr; 69 Suppl 3():554-8. PubMed ID: 22214022
[No Abstract] [Full Text] [Related]
16. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
18. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
19. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
Ma J; Yang QL; Ling Y
BMC Cancer; 2017 Feb; 17(1):132. PubMed ID: 28196490
[TBL] [Abstract][Full Text] [Related]
20. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]